Twist Bioscience Corporation (TWST)Healthcare | Diagnostics & Research | South San Francisco, United States | NasdaqGS
63.51 USD
+1.63
(2.626%)
⇧
(April 21, 2026, 1:42 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 6:37 p.m. EDT
Twist Bioscience presents a 'strong buy' consensus on Wall Street yet remains a fundamental value trap with negative earnings, alpha, and massive insider selling, creating a high-risk, high-beta instrument ($8 Risk profile, 2.2 Beta). While the recent 15.6% price rally and insider/analyst bullishness suggest a potential mid-cycle momentum trade fueled by debt refinancing and market optimism, the negative Adjusted Predicted Direction (-3.77%) and significant short ratio (13.07) warn that the recent surge may be overextended in the absence of profitability. Long-term participation should be strictly limited to residual risk traders aware that NAV erosion via dividends is not a feature, and capital preservation is secondary to asymmetric upside hopes. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.117257 |
| AutoTheta | 0.125447 |
| AutoARIMA | 0.125894 |
| AutoETS | 0.125930 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 63% |
| H-stat | 1.72 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.596 |
| Excess Kurtosis | 0.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 24.787 |
| Revenue per Share | 6.495 |
| Market Cap | 3,893,599,744 |
| Forward P/E | -33.69 |
| Beta | 2.21 |
| Profit Margins | -19.56% |
| Website | https://www.twistbioscience.com |
As of April 19, 2026, 6:37 p.m. EDT: Options activity shows a distinct disconnect between call and put sentiment. While call buyers are aggressive in ATM and slightly OTM strikes (e.g., $55, $60) for April expiration with high OI, put volume is concentrated deeply OTM ($40, $47.50), indicating limited downside protection buying at the edge but significant volume in strikes like $37.50 (July) suggesting a floor is expected higher than current lows. The low IV on long-dated puts (0.0) alongside elevated ATM call volume suggests out-of-the-money downside protection is not the primary driver; rather, speculators appear to be positioning for technical bounces near current levels, supported by the recent price climb from $43 to $59.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.67514884 |
| Address1 | 681 Gateway Boulevard |
| All Time High | 214.07 |
| All Time Low | 11.46 |
| Ask | 80.03 |
| Ask Size | 2 |
| Audit Risk | 1 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,278,340 |
| Average Daily Volume3 Month | 1,287,419 |
| Average Volume | 1,287,419 |
| Average Volume10Days | 1,278,340 |
| Beta | 2.207 |
| Bid | 46.57 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 7.444 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 63.505 |
| Current Ratio | 3.778 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 65.1 |
| Day Low | 62.375 |
| Debt To Equity | 24.787 |
| Display Name | Twist Bioscience |
| Earnings Call Timestamp End | 1,777,896,000 |
| Earnings Call Timestamp Start | 1,777,896,000 |
| Earnings Timestamp | 1,777,897,800 |
| Earnings Timestamp End | 1,777,897,800 |
| Earnings Timestamp Start | 1,777,897,800 |
| Ebitda | -112,748,000 |
| Ebitda Margins | -0.28795 |
| Enterprise To Ebitda | -32.897 |
| Enterprise To Revenue | 9.473 |
| Enterprise Value | 3,709,069,312 |
| Eps Current Year | -1.97 |
| Eps Forward | -1.885 |
| Eps Trailing Twelve Months | -1.27 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 48.892 |
| Fifty Day Average Change | 14.613003 |
| Fifty Day Average Change Percent | 0.29888332 |
| Fifty Two Week Change Percent | 67.514885 |
| Fifty Two Week High | 65.1 |
| Fifty Two Week High Change | -1.5949974 |
| Fifty Two Week High Change Percent | -0.02450073 |
| Fifty Two Week Low | 23.3 |
| Fifty Two Week Low Change | 40.205 |
| Fifty Two Week Low Change Percent | 1.7255366 |
| Fifty Two Week Range | 23.3 - 65.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,540,992,600,000 |
| Float Shares | 54,549,636 |
| Forward Eps | -1.885 |
| Forward P E | -33.689655 |
| Free Cashflow | -47,241,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 979 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.51623 |
| Gross Profits | 202,134,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01509 |
| Held Percent Institutions | 1.22539 |
| Implied Shares Outstanding | 61,311,704 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Long Business Summary | Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California. |
| Long Name | Twist Bioscience Corporation |
| Market | us_market |
| Market Cap | 3,893,599,744 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_242825322 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -76,583,000 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 3,793,968,243 |
| Number Of Analyst Opinions | 9 |
| Open | 63.14 |
| Operating Cashflow | -51,014,000 |
| Operating Margins | -0.31726998 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 800 719 0671 |
| Previous Close | 61.88 |
| Price Eps Current Year | -32.236042 |
| Price Hint | 2 |
| Price To Book | 8.531033 |
| Price To Sales Trailing12 Months | 9.943891 |
| Profit Margins | -0.19559 |
| Quick Ratio | 3.083 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 1.625 |
| Regular Market Change Percent | 2.6260505 |
| Regular Market Day High | 65.1 |
| Regular Market Day Low | 62.375 |
| Regular Market Day Range | 62.375 - 65.1 |
| Regular Market Open | 63.14 |
| Regular Market Previous Close | 61.88 |
| Regular Market Price | 63.505 |
| Regular Market Time | 1,776,793,333 |
| Regular Market Volume | 793,121 |
| Return On Assets | -0.13487001 |
| Return On Equity | -0.16794 |
| Revenue Growth | 0.169 |
| Revenue Per Share | 6.495 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 61,311,704 |
| Shares Percent Shares Out | 0.2308 |
| Shares Short | 14,149,704 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 12,726,314 |
| Short Name | Twist Bioscience Corporation |
| Short Percent Of Float | 0.2974 |
| Short Ratio | 13.07 |
| Source Interval | 15 |
| State | CA |
| Symbol | TWST |
| Target High Price | 58.0 |
| Target Low Price | 36.0 |
| Target Mean Price | 52.55556 |
| Target Median Price | 55.0 |
| Total Cash | 197,948,992 |
| Total Cash Per Share | 3.229 |
| Total Debt | 113,050,000 |
| Total Revenue | 391,556,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.27 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 36.4401 |
| Two Hundred Day Average Change | 27.0649 |
| Two Hundred Day Average Change Percent | 0.7427229 |
| Type Disp | Equity |
| Volume | 793,121 |
| Website | https://www.twistbioscience.com |
| Zip | 94,080 |